Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MerLion Preps Finafloxacin For Phase III As Advantages Confirmed

This article was originally published in PharmAsia News

Executive Summary

Singapore-based MerLion is planning to take its lead development project, the antibiotic finafloxacin, into a Phase III program for urinary tract infections after Phase II results showed advantages over the current standard of care ciprofloxacin, along with rapid, broad activity and potential for the easy switching of patients from intravenous to oral dosing.

You may also be interested in...



Second Biogen/Eisai Antibody Moves AHEAD, In Asymptomatic Alzheimer’s

More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.

Early Promise Of NextCure’s Novel IO Candidate Continues To Fade

Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.

2020 VC Landscape: Reviewing The First Six Months

A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel